Efficacy and safety in mice of repeated, lifelong administration of an ANGPTL3 vaccine

Previously, we reported that an ANGPTL3 vaccine is a hopeful therapeutic option against dyslipidemia. In our current study, we assess durability and booster effects of that vaccine over a period representing a mouse’s lifespan. The vaccine remained effective for over one year, and booster vaccinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukami, Hirotaka, Morinaga, Jun, Nakagami, Hironori, Hayashi, Hiroki, Okadome, Yusuke, Matsunaga, Eiji, Kadomatsu, Tsuyoshi, Horiguchi, Haruki, Sato, Michio, Sugizaki, Taichi, Miyata, Keishi, Torigoe, Daisuke, Mukoyama, Masashi, Morishita, Ryuichi, Oike, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620388/
https://www.ncbi.nlm.nih.gov/pubmed/37914738
http://dx.doi.org/10.1038/s41541-023-00770-3
Descripción
Sumario:Previously, we reported that an ANGPTL3 vaccine is a hopeful therapeutic option against dyslipidemia. In our current study, we assess durability and booster effects of that vaccine over a period representing a mouse’s lifespan. The vaccine remained effective for over one year, and booster vaccination maintained suppression of circulating triglyceride levels thereafter without major adverse effects on lungs, kidneys, or liver, suggesting vaccine efficacy and safety.

Ejemplares similares